Knight Therapeutics (TSE:GUD) Price Target Raised to C$5.40

Knight Therapeutics (TSE:GUD) had its target price upped by Stifel Nicolaus from C$5.25 to C$5.40 in a research report released on Wednesday, BayStreet.CA reports. Stifel Nicolaus currently has a hold rating on the stock.

A number of other equities analysts have also recently issued reports on GUD. Royal Bank of Canada lifted their target price on shares of Knight Therapeutics from C$6.50 to C$7.00 and gave the stock an outperform rating in a research report on Friday, March 22nd. Raymond James lifted their price objective on Knight Therapeutics from C$7.00 to C$7.50 and gave the stock an outperform rating in a research report on Wednesday, March 6th.

Knight Therapeutics Stock Up 1.5 %

GUD opened at C$5.91 on Wednesday. The company has a debt-to-equity ratio of 9.25, a quick ratio of 1.79 and a current ratio of 3.20. The company has a market cap of C$597.91 million, a price-to-earnings ratio of -36.38, a PEG ratio of -1,013.50 and a beta of 0.49. Knight Therapeutics has a one year low of C$4.35 and a one year high of C$5.95. The business’s fifty day moving average is C$5.53 and its two-hundred day moving average is C$5.32.

Knight Therapeutics (TSE:GUD) last released its quarterly earnings results on Thursday, March 21st. The company reported C($0.03) earnings per share (EPS) for the quarter, missing the consensus estimate of C$0.02 by C($0.05). Knight Therapeutics had a negative return on equity of 2.14% and a negative net margin of 5.13%. The firm had revenue of C$74.20 million for the quarter, compared to analyst estimates of C$78.37 million. Analysts anticipate that Knight Therapeutics will post 0.0202158 EPS for the current fiscal year.

Insider Buying and Selling

In other news, insider Sime Armoyan bought 351,000 shares of Knight Therapeutics stock in a transaction on Monday, March 25th. The shares were bought at an average cost of C$5.25 per share, for a total transaction of C$1,842,750.00. 46.45% of the stock is currently owned by company insiders.

About Knight Therapeutics

Knight Therapeutics Inc develops, manufactures, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices worldwide. It offers Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib for metastatic cholangiocarcinoma; Akynzeo for prevention of chemotherapy-induced acute and delayed nausea and vomiting; Aloxi for prevention of acute nausea and vomiting associated with emetogenic cancer chemotherapy; Fostamatinib for chronic immune thrombocytopenia; Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Trelstar for advanced prostate cancer; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic cancer; Halaven for metastatic breast cancer and soft tissue sarcoma; and Lenvima for advanced renal cell cancer and for differentiated thyroid cancer and unresectable hepatocellular carcinoma.